MA-WASABI-TECHNOLOGIES
9.4.2024 14:01:32 CEST | Business Wire | Press release
Wasabi Technologies, the hot cloud storage company, today introduced Wasabi AiR™, the industry's first AI-enabled intelligent media storage. Wasabi AiR combines Wasabi’s high-performance, low-cost object storage with advanced AI metadata auto-tagging and multilingual searchable speech-to-text transcription. Video files uploaded to Wasabi AiR are immediately analyzed and a second-by-second metadata index is created, enabling users to quickly find what they are looking for. Wasabi AiR greatly reduces the cost of metadata creation: with Wasabi AiR, customers pay only for the storage. There is no additional charge for use of the AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409707430/en/
In January, Wasabi announced its acquisition of Curio AI, a state-of-the-art AI platform designed specifically to analyze and index large video archives. Now users simply upload their video files to Wasabi AiR storage and the AI automatically goes to work generating a rich second-by-second metadata index. Wasabi AiR uses facial recognition, searchable speech-to-text, multi-lingual translation, speaker recognition, optical text recognition, logo identification, and sounds recognition with unparalleled accuracy. Video archives currently stored on tape can be uploaded to Wasabi AiR storage and formerly “dead” content can become a new source of revenue and user engagement. Wasabi AiR is purpose-built for use cases including:
- Post-production: Quickly find and assemble video for news packages, highlight reels, social media content and more in real time to enable production teams to focus on creativity without being bogged down searching for content
- Sponsorship and marketing ROI: Find logos for sponsorship attribution with ease for ROI analysis
- Geo-diversity: Tailor content to specifically meet the requirements of geo-diverse audiences
“Wasabi AiR introduces a solution to a persistent 25-year-old challenge, combining AI-driven search capabilities with high-performance cloud storage,” said Dave McCarthy, research vice president at IDC. “This marks a transformative shift in media management, offering efficiency and accessibility for businesses dealing with massive unstructured data. Wasabi AiR represents a significant advancement in tackling the longstanding issue of managing extensive data archives, within a substantial market for intelligent media storage solutions."
“Why move to the cloud if you still can’t find anything?” said David Friend, co-founder and chief executive officer, Wasabi Technologies. “Object storage without metadata is like a library without a catalog. Wasabi AiR works right out of the box and it’s as simple to use as popular search engines. For example, if it finds a face that it doesn’t recognize, it asks ‘Who is this?’ Using a simple UI, the user can train their own models. You can have tens of thousands of hours of video, and Wasabi AiR will take you right to the moment you are looking for. And you can search as much as you want – we only charge for the storage.”
Transformative Price Predictability and Performance Accuracy
Media organizations are operating under tighter deadlines and narrower profit margins and are looking for ways to speed production workflows while controlling costs. Wasabi AiR’s inexpensive, capacity-based pricing allows users the freedom to work with their content without being penalized with unpredictable fees for AI analysis, egress, or API requests, at a price up to 80% less than competitors. Both source files and metadata are owned exclusively by each customer – Wasabi never uses our customer’s proprietary data to train models that others can use. Files and metadata are secure and protected from ransomware, disasters or accidental deletions by Wasabi’s immutable storage and unique multi-user authentication.
“Wasabi AiR significantly reduces our manual efforts due to its seamless use of AI recognition technology to identify, organize and categorize files,” said Drew Crisp, Senior Vice-President of Digital at Liverpool Football Club. “At the club we handle extensive media content, and so this enhanced efficiency could really help us to locate specific content quickly and accurately within our archive, and create new content streams quickly, empowering our creativity and innovation. Wasabi AiR transcends mere storage; it will become another key to unlocking the full potential of our content.”
Learn more:
- Wasabi AiR is available this quarter. Please visit here or stop by the Wasabi booth SL8117 at NAB April 14-17 for a demo or book a meeting to learn more about how Wasabi cloud storage can enhance media workflows
- See the savings Wasabi AiR enables with the cost calculator based on hours of video, bit rates and monthly amount of downloaded content
About Wasabi Technologies
Recognized as one of the technology industry’s fasting growing companies, Wasabi is on a mission to store the world's data by making cloud storage affordable, predictable and secure. With Wasabi, visionary companies gain the freedom to use their data whenever they like without being hit with unpredictable fees or vendor lock-in. Instead, they’re free to build best-of-breed solutions with the industry’s fastest-growing ecosystem of independent cloud application partners. Customers and partners all over the world trust Wasabi to help them put their data to work so they can unlock their full potential. Visit wasabi.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409707430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
